Key result
TAVI yields comparable 5-year survival in nonagenarians versus younger patients and the matched general population.
Why the study?
The efficacy and validity of transcatheter aortic valve implantation (TAVI) in very elderly patients, specifically nonagenarians, remain unclear.
Does TAVI provide acceptable early and long-term clinical outcomes in nonagenarians with severe aortic stenosis compared to younger patients?
Observational (n=206)
No
Does TAVI provide acceptable early and long-term clinical outcomes in nonagenarians with severe aortic stenosis compared to younger patients?
TAVI provides acceptable early and 5-year clinical outcomes in selected nonagenarians with severe aortic stenosis, comparable to younger patients and the matched general population.
Answers are grounded in this paper and cite their sources.
Supports TAVI consideration in selected nonagenarians; leaves open randomized confirmation of age-independent outcomes.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly being performed in very elderly patients, although its efficacy and validity remain unclear. This study evaluated real-world TAVI outcomes in Japanese nonagenarians with severe aortic stenosis. METHODS AND RESULTS: This single-center study retrospectively assessed the early and long-term clinical outcomes of TAVI in nonagenarians (n=35) and in patients aged <90 years (group Y; n=171). There were no in-hospital deaths in either group. The device success rate and early safety were comparable between the 2 groups. The 5-year rates of freedom from cardiac events and deaths were equivalent in both groups. The cumulative survival rate at 5 years was non-significantly lower in nonagenarians (32.6% in nonagenarians vs. 57.5% in patients aged <90 years, P=0.49). There were no differences in the 5-year survival between nonagenarians after TAVI and the sex- and age-matched populations (P=0.18). The Cox regression model revealed that lower hemoglobin levels were associated with all-cause mortality (P=0.02), and age ≥90 years was not associated with all-cause mortality. CONCLUSIONS: The early and long-term clinical outcomes of TAVI for selected Japanese nonagenarians were comparable to those in patients aged <90 years. Nonagenarians who underwent TAVI achieved an acceptable prognosis compared to the sex- and age-matched population; thus, TAVI appears to be effective for treating aortic stenosis in Japanese nonagenarians.
No takes yet. Share an insight, caveat, or question.
Kurazumi et al. (2022) conducted an observational in Severe aortic stenosis (n=206). Age ≥90 years (Nonagenarians) vs. Age <90 years was evaluated on 5-year cumulative survival rate (p=0.49). In Japanese patients undergoing TAVI, 5-year cumulative survival was not significantly different between nonagenarians and patients aged <90 years (32.6% vs. 57.5%, P=0.49), and was comparable to the age- and sex-matched general population.
Synapse has enriched 10 related papers. Consider them for comparative context: